Victrex (VCT) H1 2025 earnings summary

Executive summary

• H1 2025 sales volumes rose 16% year-over-year to 2,018 tonnes, led by strong growth in value-added resellers (+30%), electronics (+17%), and energy/industrial (+15%), while transport declined 2% and medical was flat.

• Revenue increased 5% to £145.9m (8% in constant currency), but gross profit declined 4% to £64.3m due to less favorable sales mix, FX, and China ramp-up costs.

• Underlying PBT was £23.2m, down 17% year-on-year but flat in constant currency; reported PBT was £17.2m, up due to lower exceptional items.

• Strong cash conversion at 128%, with operating cash flow of £30.7m–£34.6m and free cash flow of £22.5m, supported by lower CapEx and inventory unwind.

• Major commercial milestone achieved with TechnipFMC order for Petrobras under the Magma programme, supporting long-term growth.

Financial highlights

• Gross margin fell 390bps to 44.1%, mainly due to China plant ramp-up costs, FX, and sales mix; excluding China, gross margin would have been 46.6%.

• ASP declined 10% to £72.3/kg, primarily due to mix and FX; guidance for FY25 ASP is £72–£75/kg.

• Interim dividend maintained at 13.42p per share, with strong cash flow supporting payout despite earnings pressure.

• Net debt at £40.7m, improved from £49.8m in H1 2024, with cash and equivalents of £25.4m.

• CapEx at £8.6m (vs. £21.8m prior year), trending toward 8–10% of revenue.

Outlook and guidance

• Upgraded FY25 volume growth guidance to high single digits, reflecting strong H1 momentum despite macro uncertainty.

• Gross margin guidance for FY25 is 45–47%, below original guidance due to mix and China impact.

• Targeting substantial H2 underlying PBT growth versus H1, with full-year PBT growth in constant currency despite £8–9m FX headwind.

• Medical segment expected to improve in H2, with non-spine applications leading recovery.

• CapEx expected at lower end of 8–10% of revenue; continued strong cashflow anticipated.